Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

Revolution Medicines announced preclinical data for RM-055, a novel class of mutant-targeted catalytic RAS(ON) inhibitors, at the AACR Annual Meeting. In xenograft models of pancreatic, lung, and colorectal cancers, RM-055 drove deep and durable tumor regressions and overcame resistance to prior RAS inhibition.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.